Experienced in Adenoid Cystic Carcinoma

Dr. Mrinal M. Gounder

Oncology
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
Offers Telehealth
Experienced in Adenoid Cystic Carcinoma
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mrinal Gounder is an Oncologist in New York, New York. Dr. Gounder is rated as an Experienced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Epithelioid Sarcoma, Liposarcoma, and Liver Embolization.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Adenoid Cystic Carcinoma.

Specialties
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MEMORIAL SOLID TUMOR GROUP
1275 York Ave, New York, NY 10065
Other Locations
MEMORIAL SOLID TUMOR GROUP
160 E 53rd St, New York, NY 10022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: Oraxol
Study Phase: Phase 2
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drug: Tegavivint
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

122 Total Publications

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025
Similar Doctors
Distinguished in Adenoid Cystic Carcinoma
Dr. David G. Pfister
Oncology
Distinguished in Adenoid Cystic Carcinoma
Dr. David G. Pfister
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Pfister is an Oncologist in New York, New York. Dr. Pfister has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Thyroid Cancer.

Distinguished in Adenoid Cystic Carcinoma
Dr. Lara A. Dunn
Oncology
Distinguished in Adenoid Cystic Carcinoma
Dr. Lara A. Dunn
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lara Dunn is an Oncologist in New York, New York. Dr. Dunn has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Sinus Cancer, and Desmoplastic Small Round Cell Tumor.

Distinguished in Adenoid Cystic Carcinoma
Dr. Doru M. Paul
Hematology Oncology | Oncology | Hematology
Distinguished in Adenoid Cystic Carcinoma
Dr. Doru M. Paul
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

1305 York Ave, 
New York, NY 
 (0.1 miles away)
646-962-6200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Doru Paul is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Paul is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Familial Pancreatic Cancer, Colorectal Cancer, and Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gounder's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 15 Distinguished Conditions
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile